Organon Gets 24% Sun Pharma Buyout Bid at $13.25 Floor Price
NEW YORK, May 1 —
Sun Pharma offered to buy Organon for all cash at a 24% premium, and Organon promptly cancelled its Q1 earnings call.
- OGN trading near $13.25 with a 24% all-cash takeout premium on the table from Sun Pharma
- 3.6x forward P/E on $6.2bn TTM revenue, the kind of multiple that only shows up when the market has stopped believing the cash flows
- Q1 CY2026 revenue missed estimates, margins compressed to 3%, and the earnings call was scrapped
What Actually Happened
Two stories collapsed into one. Organon missed Q1 revenue, watched margins compress to 3%, and pulled its earnings call. Pulling the call is the tell. Public companies do not cancel scheduled investor communications during a quiet quarter. They cancel them when lawyers tell them to. Sun Pharma's all-cash offer at a 24% premium is the reason. The European Commission also approved POHERDY, the pertuzumab biosimilar with Shanghai Henlius, but that is a footnote when a strategic acquirer is on the doorstep. Vanguard Capital Management disclosing a 13.7 million share position in the same window is not a coincidence either: arbitrage desks tend to show up after the bid leaks.
The Catch
A 24% premium on a $13 stock is a $16-ish takeout, and that math is fine if the deal closes. It is less fine if it does not. Sun Pharma is an Indian generics giant buying a US women's health and biosimilars portfolio. Antitrust review will not be a rubber stamp, particularly on overlapping contraceptive and biosimilar lines. The 3.6x forward multiple is telling you the market thinks the standalone business is impaired. If regulators block the deal, the floor disappears and you are left holding a 3% margin business with a missed quarter and no earnings call.
Bottom Line
Organon is no longer a fundamentals story. It is a deal-spread trade. Value investors who liked the cheap multiple have already won, in cash, if the deal closes. Growth investors should not be here. The one number to watch is the official Sun Pharma offer price per share. Until that prints, the 24% premium is a rumor with a reasonable amount of evidence behind it.
Want a full breakdown of Organon's biosimilars pipeline and the deal math? Generate a custom report at /stock/ogn.
Basis Report does not hold positions in securities discussed. This is not investment advice.